Louwai

Doctor, neuroscientist, founder | CEO of CoSyne Therapeutics | @Harvard, @UniofOxford, @Cambridge_uni, @Kennedyscholars

[Louwai @Louwai1]

British commentary being a caricature of itself.

[BBC Breakfast @BBCBreakfast]

Elon Musk's electric car manufacturer, Tesla, has unveiled what it calls a 'flying car'.

On #BBCBreakfast Charlie & Naga looked at images of the two-seater Roadster - which has been developed in collaboration with the rocket company, Space X

https://t.co/uAEXR9M77d

[Louwai @Louwai1]

@Jack_O_Meara Beautifully put

[Louwai @Louwai1]

Great founder, testament to pain tolerance.

[Pari Singh @parisingh]

Flow has raised a $50M Series B at a $750M valuation, co-led by Antonio Gracias (Valor) and Gavin Baker (Atreides) with Sequoia Capital, Roelof Botha (SpaceX, Block), and more.

When I became a mechanical engineer, I wanted to invent. In reality, 90% of the day to day execution work (CAD, excel, sim) was digital manual labour. That’s about to flip. The engineer’s role will change more profoundly than at any point since the invention of CAD, with humans focusing on invention, architecture, tradeoffs and judgement calls, and agents taking the grunt work.

Anduril, Joby, Stoke Space, Rivian & many more - Flow is now the default platform for requirements and verification for frontier hardware teams. But it’s not just next-gen anymore. Industry giants including General Motors PPU and Volkswagen & Rivian’s joint venture (RV Tech) are reshaping their core development practices with Flow’s AI.

The revolution is just starting. Models are getting better quickly at CAD, analysis, simulation, and tool use. In the next year, AI will move from integrating the work to doing the work.

One day, this shift won't just enable us to iterate faster, it will enable us to design a class of products that we could not have dreamt of before.

We’re hiring.

[Louwai @Louwai1]

@parisingh Congratulations Pari! 🥳 so well deserved

[scott belsky @scottbelsky]

the more people you consult for advice, the more likely you’ll make a bad/average decision.

(1) ppl are, on average, risk averse...and, in quantity, will blunt your boldness.
(2) ppl may hate/envy opportunities they lack.
(3) ppl tend to mix cynicism (bad) w/ criticism (good)

[Louwai @Louwai1]

@Ronalfa If you’re interested in GBM let’s chat, we have been working on this for 6 years and have a very large biobank of primaries

[Louwai @Louwai1]

@Lukketex @nntaleb

[Louwai @Louwai1]

@BobEUnlimited Congratulations Bob! 🥳

[Louwai @Louwai1]

Counter transference is a concept in psychiatry where the way a patient makes you feel can be a clue to the diagnosis. In business, the way someone makes you feel is a clue to what they want. Some make you feel stupid, some make you feel special. Both are trying to get something from you. The way they make you feel is a sign.

[Louwai @Louwai1]

Continuing the "stuff you learn in medicine that helps you run a company" series:

[Louwai @Louwai1]

@BobEUnlimited Love this. People rarely appreciate the degree of social resistance that is triggered by pursuing non-consensus ideas.

[Louwai @Louwai1]

@hkanji The irony is satisfying when they can’t speak English

[Louwai @Louwai1]

@parisingh @sequoia @patrickc @collision @david_helgason @roelofbotha Amazing! Well deserved Pari!

[Louwai @Louwai1]

People care too much about two things:

1) social status
2) not looking stupid

If you can emancipate your brain from these traps you will find the universe is much more malleable to your will than you realise.

[Louwai @Louwai1]

Extreme pessimism and extreme optimism converge on the same behaviour: laziness.

[Louwai @Louwai1]

1. Just because something isn't your fault, doesn't mean you aren't responsible for it. If a patient comes into the emergency room after a car accident, it's not your fault but it is your responsibility as the doctor. The same is true for anything that goes wrong in your company.

[Louwai @Louwai1]

Continuing the "stuff you learn in medicine that helps you run a company" series:

[Bob Elliott @BobEUnlimited]

.@CoSyneTx's revolutionary approach combines AI drug discovery with immediate lab testing on proprietary set brain tumor cells to establish efficacy, cutting time from identification to patient treatment from decades to months.

More in their recent video
https://t.co/HbCyfqdU0z

[Louwai @Louwai1]

Our findings. Does anyone else agree?